XNYSSENS
Market cap349mUSD
Jan 15, Last price
0.73USD
1D
-2.17%
1Q
108.34%
Jan 2017
-72.69%
IPO
-78.23%
Name
Senseonics Holdings Inc
Chart & Performance
Profile
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 22,390 36.62% | 16,389 19.85% | |||||||
Cost of revenue | 68,051 | 53,382 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (45,661) | (36,993) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 18,703 | ||||||||
Tax Rate | |||||||||
NOPAT | (45,661) | (55,696) | |||||||
Net income | (60,392) -142.49% | 142,119 -144.72% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 7,376 | 31,604 | |||||||
BB yield | -2.28% | -4.96% | |||||||
Debt | |||||||||
Debt current | 368 | 15,579 | |||||||
Long-term debt | 53,991 | 61,761 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 102 | 89,706 | |||||||
Net debt | (55,097) | (78,928) | |||||||
Cash flow | |||||||||
Cash from operating activities | (70,163) | (66,312) | |||||||
CAPEX | (350) | (312) | |||||||
Cash from investing activities | 89,713 | 26,882 | |||||||
Cash from financing activities | 20,366 | 41,762 | |||||||
FCF | (53,305) | (56,793) | |||||||
Balance | |||||||||
Cash | 109,456 | 144,015 | |||||||
Long term investments | 12,253 | ||||||||
Excess cash | 108,336 | 155,449 | |||||||
Stockholders' equity | (831,083) | (771,408) | |||||||
Invested Capital | 952,414 | 933,189 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 567,974 | 618,206 | |||||||
Price | 0.57 -44.65% | 1.03 -61.42% | |||||||
Market cap | 323,802 -49.15% | 636,752 -43.53% | |||||||
EV | 306,361 | 595,480 | |||||||
EBITDA | (44,384) | (36,008) | |||||||
EV/EBITDA | |||||||||
Interest | 11,110 | 18,703 | |||||||
Interest/NOPBT |